Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation

AB-423 is a member of the sulfamoylbenzamide (SBA) class of hepatitis B virus (HBV) capsid inhibitors in phase 1 clinical trials. In cell culture models, AB-423 showed potent inhibition of HBV replication (50% effective concentration [EC(50)] = 0.08 to 0.27 μM; EC(90) = 0.33 to 1.32 μM) with no sign...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Antimicrob Agents Chemother
Glavni autori: Mani, Nagraj, Cole, Andrew G., Phelps, Janet R., Ardzinski, Andrzej, Cobarrubias, Kyle D., Cuconati, Andrea, Dorsey, Bruce D., Evangelista, Ellen, Fan, Kristi, Guo, Fang, Guo, Haitao, Guo, Ju-Tao, Harasym, Troy O., Kadhim, Salam, Kultgen, Steven G., Lee, Amy C. H., Li, Alice H. L., Long, Quanxin, Majeski, Sara A., Mao, Richeng, McClintock, Kevin D., Reid, Stephen P., Rijnbrand, Rene, Snead, Nicholas M., Micolochick Steuer, Holly M., Stever, Kim, Tang, Sunny, Wang, Xiaohe, Zhao, Qiong, Sofia, Michael J.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2018
Teme:
Antiviral Agents
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5971612/
https://ncbi.nlm.nih.gov/pubmed/29555628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00082-18
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items